NASDAQ:GNFTGENFIT S A/ADR Stock Price, Forecast & News

GENFIT S A/ADR's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNFT shares have decreased by 61.9% and is now trading at $5.42. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GENFIT S A/ADR in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GENFIT S A/ADR.

GENFIT S A/ADR is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for GENFIT S A/ADR.

9 brokers have issued 1-year price objectives for GENFIT S A/ADR's shares. Their forecasts range from $7.00 to $174.00. On average, they anticipate GENFIT S A/ADR's stock price to reach $45.20 in the next twelve months. This suggests a possible upside of 733.9% from the stock's current price. View analysts' price targets for GENFIT S A/ADR.

Media stories about GNFT stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GENFIT S A/ADR earned a news impact score of -1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about GENFIT S A/ADR.

Some companies that are related to GENFIT S A/ADR include Replimune Group (REPL), Cellectis (CLLS), Krystal Biotech (KRYS), Vericel (VCEL), Osiris Therapeutics (OSIR), Proteon Therapeutics (PRTO), Autolus Therapeutics (AUTL), Agenus (AGEN), Avrobio (AVRO), AVITA MED LTD/S (RCEL), Vaxart (VXRT), Aerie Pharmaceuticals (AERI), Oyster Point Pharma (OYST), Aptose Biosciences (APTO) and Orchard Therapeutics (ORTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GENFIT S A/ADR investors own include Intercept Pharmaceuticals (ICPT), InterDigital Wireless (IDCC), Stag Industrial (STAG), Amarin (AMRN), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Vaxart (VXRT), Agile Therapeutics (AGRX), Aimmune Therapeutics (AIMT) and Advanced Micro Devices (AMD).

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

GENFIT S A/ADR trades on the NASDAQ under the ticker symbol "GNFT."

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GNFT stock can currently be purchased for approximately $5.42.

GENFIT S A/ADR has a market capitalization of $205.04 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. GENFIT S A/ADR employs 148 workers across the globe.

The official website for GENFIT S A/ADR is www.genfit.com.

GENFIT S A/ADR's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]